FIELD: pharmaceutics; medicine.
SUBSTANCE: object 1 is a combined drug for use in the treatment of cancer, containing a pharmaceutical composition containing a smallpox vaccine virus as an active ingredient, where the smallpox vaccine virus is (1) a smallpox vaccine virus including polynucleotide encoding interleukin-7 (hereinafter – IL-7) and a smallpox vaccine virus including polynucleotide encoding interleukin-12 (hereinafter – IL-12), or (2) a smallpox vaccine virus including polynucleotide encoding IL-7 and polynucleotide encoding IL-12, and a pharmaceutical composition containing an immune control point inhibitor. Object 2 is a method for the treatment of cancer, including administration of the immune control point inhibitor and the smallpox vaccine virus.
EFFECT: antitumor effect and full remission induction effect revealing relatively to remote tumor, into which a smallpox vaccine virus was not administered, in case of the use of the smallpox vaccine virus in a combination with an immune control point inhibitor.
16 cl, 1 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW GENETICALLY ENGINEERED SMALLPOX VACCINE VIRUSES | 2017 |
|
RU2757933C2 |
| COMBINATION OF ONCOLYTIC VIRUS WITH MODULATORS OF IMMUNOLOGICAL CONTROL POINTS | 2015 |
|
RU2705780C2 |
| ONCOLYTIC VIRUS FOR IMMUNOLOGIC CONTROL POINT MODULATORS EXPRESSION | 2015 |
|
RU2696312C2 |
| COMBINATION THERAPY FOR TREATING CANCER WITH POXVIRUS EXPRESSING TUMOUR ANTIGEN AND ANTAGONIST AND/OR AGONIST OF IMMUNE CHECKPOINT INHIBITOR | 2014 |
|
RU2714142C2 |
| M2-DEFECTIVE POXVIRUS | 2019 |
|
RU2819245C2 |
| COMBINATION THERAPY OF ANTIBODY TO PROGASTRIN AND IMMUNOTHERAPY FOR CANCER TREATMENT | 2018 |
|
RU2784604C2 |
| COMBINED IMMUNOTHERAPEUTIC APPROACH TO CANCER TREATMENT | 2015 |
|
RU2716821C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| COMBINED THERAPY FOR TREATING CANCER USING A RECOMBINANT POXVIRUS EXPRESSING A TUMOR ANTIGEN AND AN ANTAGONIST OR AGONIST OF AN IMMUNE CONTROL POINT MOLECULE | 2015 |
|
RU2724433C2 |
| VACCINE ONCOLYTIC VERSION AND METHODS OF ITS USE | 2020 |
|
RU2805179C1 |
